These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 29807471)

  • 1. Comparison of International Regulations for Written Medicine Information (WMI) on Prescription Medicines.
    Yuan HT; Raynor DK; Aslani P
    Ther Innov Regul Sci; 2019 Mar; 53(2):215-226. PubMed ID: 29807471
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Future development of global regulations of Chinese herbal products.
    Fan TP; Deal G; Koo HL; Rees D; Sun H; Chen S; Dou JH; Makarov VG; Pozharitskaya ON; Shikov AN; Kim YS; Huang YT; Chang YS; Jia W; Dias A; Wong VC; Chan K
    J Ethnopharmacol; 2012 Apr; 140(3):568-86. PubMed ID: 22373513
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Beyond needs and expectations: identifying the barriers and facilitators to written medicine information provision and use in Australia.
    Hamrosi KK; Aslani P; Raynor DK
    Health Expect; 2014 Apr; 17(2):220-31. PubMed ID: 22390211
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Written medicine information from English-speaking countries--how does it compare?
    Luk A; Tasker N; Raynor DK; Aslani P
    Ann Pharmacother; 2010 Feb; 44(2):285-94. PubMed ID: 20103613
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhancing patient education about medicines: factors influencing reading and seeking of written medicine information.
    Koo M; Krass I; Aslani P
    Health Expect; 2006 Jun; 9(2):174-87. PubMed ID: 16677196
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Legislative and non-legislative regulations concerning Rx drug advertisement in the European Union and the United States--comparative analysis.
    Czerw A; Religioni U
    Acta Pol Pharm; 2012; 69(4):779-87. PubMed ID: 22876622
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recognition of pharmaceutical prescriptions across the European Union: a comparison of five Member States' policies and practices.
    Miguel LS; Augustin U; Busse R; Knai C; Rubert G; Sihvo S; Baeten R
    Health Policy; 2014 Jun; 116(2-3):206-13. PubMed ID: 24290875
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The development and evaluation of written medicines information for type 2 diabetes.
    Lee DY; Armour C; Krass I
    Health Educ Res; 2007 Dec; 22(6):918-30. PubMed ID: 17947249
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Orphan drugs: the regulatory environment.
    Franco P
    Drug Discov Today; 2013 Feb; 18(3-4):163-72. PubMed ID: 22981668
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual regulatory pharmaceutical labeling schemes; the role of the Federal Preemption Doctrine.
    Fern FH; Bartell L
    Health Matrix; 1987; 5(3):17-23. PubMed ID: 10285381
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Package leaflets of the most consumed medicines in Portugal: safety and regulatory compliance issues. A descriptive study.
    Pires C; Vigário M; Cavaco A
    Sao Paulo Med J; 2015; 133(2):91-100. PubMed ID: 25337666
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessing the problem of counterfeit medications in the United Kingdom.
    Jackson G; Patel S; Khan S
    Int J Clin Pract; 2012 Mar; 66(3):241-50. PubMed ID: 22070229
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Consumer understanding of prescription drug information: an illustration using an antidepressant medication.
    Shiffman S; Gerlach KK; Sembower MA; Rohay JM
    Ann Pharmacother; 2011 Apr; 45(4):452-8. PubMed ID: 21427296
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patient access to medicines in two countries with similar health systems and differing medicines policies: Implications from a comprehensive literature review.
    Babar ZU; Gammie T; Seyfoddin A; Hasan SS; Curley LE
    Res Social Adm Pharm; 2019 Mar; 15(3):231-243. PubMed ID: 29678413
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pediatric drug development: ICH harmonized tripartite guideline E11 within the United States of America, the European Union, and Japan].
    Pflieger M; Bertram D
    Arch Pediatr; 2014 Oct; 21(10):1129-38. PubMed ID: 25175054
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Provision and Need for Medicine Information in Asia and Africa: A Scoping Review of the Literature.
    Nualdaisri P; Corlett SA; Krska J
    Drug Saf; 2021 Apr; 44(4):421-437. PubMed ID: 33666901
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Written patient information on prescription drugs. The evolution of government and voluntary programs in the United States.
    Nightingale SL
    Int J Technol Assess Health Care; 1995; 11(3):399-409. PubMed ID: 7591542
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advancing Best Practices for Prescription Drug Labeling.
    Bailey SC; Navaratnam P; Black H; Russell AL; Wolf MS
    Ann Pharmacother; 2015 Nov; 49(11):1222-36. PubMed ID: 26354048
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Registering medicines for low-income countries: how suitable are the stringent review procedures of the World Health Organisation, the US Food and Drug Administration and the European Medicines Agency?
    Doua JY; Van Geertruyden JP
    Trop Med Int Health; 2014 Jan; 19(1):23-36. PubMed ID: 24134396
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Readability Analysis of the Package Leaflets for Biological Medicines Available on the Internet Between 2007 and 2013: An Analytical Longitudinal Study.
    Piñero-López MÁ; Modamio P; Lastra CF; Mariño EL
    J Med Internet Res; 2016 May; 18(5):e100. PubMed ID: 27226241
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.